Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news


From To
Long-acting injectable ARVs are convenient and private, study participants report

HIV-positive people who took injectable cabotegravir + rilpivirine every four or eight weeks as antiretroviral therapy found it more convenient and discreet than daily pills, also feeling

17 January 2018
Roger Pebody
Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

10 January 2018
Teva press release
New 'mini-pillbox' device could deliver three HIV drugs in a single once-weekly dose

A new oral device that is taken once a week in a capsule could deliver two or three antiretroviral drugs and significantly reduce the risk

09 January 2018
Keith Alcorn
New long-acting, less-toxic HIV drug suppresses virus in humanized mice

A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate to enhance current HIV treatment regimens — without increasing toxic side effects, the researchers said.

08 January 2018
Yale News
FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR/3TC/TDF).

08 January 2018
Merck press release
HIV Drugs in the Pipeline: Expected Approvals for 2018

Three specialty HIV medications—three oral medications and one IV formulation—are expected to receive FDA approval in 2018. All of them are combination products geared toward improving adherence.

31 December 2017
Infectious Disease Special Edition
Dolutegravir and lamivudine potent and safe in people starting HIV therapy for the first time

The two-drug antiretroviral combination dolutegravir and lamivudine is virologically effective and safe in people starting HIV therapy for the first time, according to US research published in the

28 December 2017
Michael Carter
Could we safely reduce the frequency of treatments for HIV-positive people?

Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

08 December 2017
The Conversation
FDA Approves Juluca, the First Two-Drug HIV Regimen

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

22 November 2017
Top 10 HIV Clinical Developments of 2017

By David Alain Wohl, M.D., professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC).

19 November 2017
The Body Pro
← First12345...99Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.